Literature DB >> 31724593

Nonhemophiliac musculoskeletal pseudotumor.

Indrani Sen1, Dheepak Selvaraj1, Prabhu Premkumar1, Sunil Agarwal1.   

Abstract

A 24-year-old man presented with impending ulceration of a large thigh swelling which appeared after minor trauma. Imaging revealed a large well-encapsulated lesion with no vascularity. He was diagnosed to have a pseudotumor and underwent successful excision of the mass under blood and cryoprecipitate cover. The unusual presentation was suspected to be secondary to a transient drug-induced factor XIII deficiency because the result of the final coagulation study was normal.
© 2015 The Authors.

Entities:  

Year:  2015        PMID: 31724593      PMCID: PMC6849987          DOI: 10.1016/j.jvsc.2015.04.007

Source DB:  PubMed          Journal:  J Vasc Surg Cases        ISSN: 2352-667X


We report the management of a pseudotumor occurring due to a transient factor XIII deficiency. A pseudotumor is a chronic progressive swelling due to recurrent hemorrhage into soft tissue. Although benign, it mimics a sarcoma, hence the name. A high degree of suspicion is necessary to diagnose these slow-growing masses. Operative management requires a multidisciplinary team with experience in the management of rare bleeding disorders. The patient consented to the publication of this report.

Case report

A 24-year-old man presented with a gradually increasing swelling of the right thigh for 1 year, with skin ulceration for 1 month. He sustained minor trauma (fall onto his right leg) 1 year previously. He received empirical antituberculous treatment (ATT) elsewhere for a year. He did not have family history of bleeding disorders. On examination there was a 24-cm × 16-cm × 12-cm right upper thigh swelling with skin ulceration (Fig 1). There was no abnormal pulsation or bruit. Magnetic resonance imaging revealed a complex heterogeneous well-encapsulated lesion in the anterolateral aspect of the right thigh (Fig 2). Comparison with earlier imaging revealed an increase in the size. Adjacent bones were normal, and there were no air pockets. Duplex screening ruled out a pseudoaneurysm. Differentials considered were schwannoma or neurofibroma with necrosis, soft tissue sarcoma, or pseudotumor.
Fig 1

Clinical presentation: swelling in the right thigh with an area of ulceration (red arrow).

Fig 2

Preoperative magnetic resonance imaging shows a pseudotumor of the right thigh.

Clinical presentation: swelling in the right thigh with an area of ulceration (red arrow). Preoperative magnetic resonance imaging shows a pseudotumor of the right thigh. Coagulation profile testing revealed a hemoglobin value, total counts, and platelet counts within normal reference ranges. There was a prolonged prothrombin time, activated partial thromboplastin time (aPTT) and thrombin time, which corrected with control plasma. The prolonged aPTT did not correct with aged serum or adsorbed plasma. Factor XIII levels were 37.5%. Concentrations of Factor VII, VIII, IX, von Willebrand factor, and fibrinogen, platelet aggregometry results were within normal reference ranges. The mass was diagnosed to be a pseudotumor. Management involved a multidisciplinary team that included vascular and orthopedic surgeons, hematology and transfusion medicine physicians, and interventional radiology. After arterial embolization of branches from the internal iliac and profunda (Fig 3), the pseudotumor was excised with the patient under general anesthesia. The mass was approached by an anterolateral thigh incision from the anterior-superior iliac spine to the patella. There was no definite intermuscular plane, and an incision was made into the capsule. Two liters of altered blood and clots were suctioned out. After this decompression, the pseudotumor capsule was excised with ligation of all adherent vessels circumferentially. The surgical wound was packed, and hemostasis of the muscle bed was achieved by surgical ligation and cautery along with the use of fibrin glue and topical hemostats. The total operative blood loss was 3.51 L. Perioperative concentrations of hemoglobin, platelets, fibrinogen, prothrombin time, aPTT, and thromboelastography were used to guide replacement therapy, and 5 units of packed cells, 4 units of platelet-rich concentrates, 15 units of cryoprecipitate, and 4 units of fresh frozen plasma were administered. The excess redundant skin was excised and the wound closed in layers over a closed nonsuction drain.
Fig 3

Embolization for pseudotumor of the right thigh. Branches from the internal iliac (top left) and profunda (top right). Arterial embolization with reduction in capsule vadcularity (bottom row).

Embolization for pseudotumor of the right thigh. Branches from the internal iliac (top left) and profunda (top right). Arterial embolization with reduction in capsule vadcularity (bottom row). Postoperatively, the patient did not require continued support with blood or blood products. The drain contained serosanguineous fluid for the first 2 days, after which contents were serous. It was removed in a week, after the volume reduced to <10 mL. The pathology report was consistent with an organized hematoma.

Discussion

Hemophilic pseudotumor is an encapsulated hematoma with calcification and ossification caused by recurrent bleeding in patients with coagulation disorders. It was first described by Valderrama and Matthews. Soft tissue chronic expanding hematomas are a similar condition where there is an increasing hematoma present >1 month after the inciting trauma. However, these lack a definitive etiology, and patients have no underlying coagulation abnormality. We searched all available MEDLINE, Science Direct, and Ovid records using “hemophilia, hemophiliac, pseudotumor, cyst, factor XIII, acquired, chronic hematoma, and surgery” as search words. This is the first report of successful operative management of a large pseudotumor with an acquired transient coagulation disorder.3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 Pseudotumors occur in 1% to 2 % of patients with hemophilia, platelet disorders, or other factor deficiencies. With early detection of muscle bleeding in patients with hemophilia, occurrence of life-threatening pseudotumors are rare but may still be seen where factor and blood product support is not easily available. Clinically, they present with a slow-growing localized mass present for many years. There are two subtypes. Proximal pseudotumors occur due to subperiosteal, intraosseous, or intramuscular bleeding in the adult femur or pelvic areas prone to repetitive trauma. These do not respond to conservative treatment. Distal pseudotumors occur in epiphyseal growth plates in children and may resolve with replacement therapy and immobilization. Pressure effects on adjacent soft tissue may lead to skin necrosis, bleeding, pain, neurologic deficits, contractures, and impaired mobility. Secondary infection or ruptures into an adjacent viscus are rare complications. Imaging is the mainstay of diagnosis. A pseudotumor in soft tissue can be classified as intramuscular or extramuscular (interfascial, subcutaneous, osseous, and subperiosteal). Ultrasound imaging helps in the diagnosis, differentiation from a pseudoaneurysm, and follow-up of a smaller lesion. Computed tomography reveals mass lesions of variable density, calcification, focal bone formation, erosion, periosteal reaction, or medullary destruction. The presence of gas indicates secondary infection. Enhanced computed tomography defines the outlines and wall thickness of the peripheral enhancing capsule, relation to the vascular structures, and rules out a pseudoaneurysm. Magnetic resonance imaging can distinguish between acute (1-6 days) and chronic hemorrhage and differentiate the mass from soft tissue sarcomas, parasitic cysts, or other tumors. Management is guided by the site, size, rate of growth, or presence of pressure effects. The risk of blood loss and need for blood/product support makes preoperative diagnosis a must. Differentiation from a soft tissue tumor may rarely necessitate a biopsy. Conservative measures—factor replacement, monitoring with radiologic imaging, and drainage or aspiration—are indicated in small acute lesions, with repeat imaging to guide duration of treatment. Aspiration/drainage in chronic lesions is usually unsuccessful because of the presence of organized hematoma, which cannot be evacuated without operative intervention.1, 2 Fibrin glue injection, bone graft, hydroxyapatite filling, arterial embolization, or radiotherapy are used as adjuncts. Incision and drainage is contraindicated in large lesions due to the risk of massive hemorrhage, persistent oozing from the remnant capsule, and infection.1, 2 Embolization reduces the blood supply to the densely adherent capsule in large tumors, reducing bleeding from the muscle bed.18, 19 Surgical excision under blood/product cover is indicated for larger lesions or when complications occur. Amputation may be necessary in patients who have a nonfunctional limb, long-bone fracture, uncontrollable hemorrhage, or a massive lesion with unacceptable risk from excision. Pseudotumors occurring in patients with coagulopathies other than hemophilia, such as acquired factor XIII deficiency,3, 4, 5, 6 are even rarer. Acquired factor XIII deficiency can occur due to decrease protein synthesis or autoantibodies in malignancy, irritable bowel disease, autoimmune disorders, pulmonary thromboembolism, stroke, cirrhosis, sepsis, disseminated intravascular coagulation, major surgery, or medications. Medications can cause acquired XIII deficiency. Use of isoniazid, penicillin, phenytoin, or practolol is associated with this complication, and patients present with intramuscular/retroperitoneal bleeding occurring 1 to 8 years after the initiation of medication. It can be fatal if not treated promptly. Stopping the causative medication reverses the coagulopathy in weeks to months. Other medications, such as prednisolone, cyclophosphamide, and rituximab are used for treatment when indicated.8, 9 Operative intervention is necessary in large lesions or when complications occur.

Conclusions

Successful surgical management of pseudotumors requires a multidisciplinary team with experience in management of rare bleeding disorders.
  18 in total

Review 1.  Haemophilic cysts (pseudotumours).

Authors:  E C Rodriguez-Merchan
Journal:  Haemophilia       Date:  2002-05       Impact factor: 4.287

2.  On the natural history of hemophilic pseudotumor.

Authors:  A K Ahlberg
Journal:  J Bone Joint Surg Am       Date:  1975-12       Impact factor: 5.284

3.  Guidelines for the management of hemophilia.

Authors:  A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal:  Haemophilia       Date:  2012-07-06       Impact factor: 4.287

4.  Case report of an acquired factor XIII inhibitor: diagnosis and management.

Authors:  Thomas F Gregory; Barry Cooper
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-07

5.  An acquired inhibitor to factor XIII.

Authors:  N B McDevitt; J McDonagh; H L Taylor; H R Roberts
Journal:  Arch Intern Med       Date:  1972-11

6.  Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder.

Authors:  S Lopaciuk; K Bykowska; J M McDonagh; R P McDonagh; W J Yount; C R Fuller; L Cooperstein; A Gray; L Lorand
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

7.  Enlarging intramuscular hematoma and fibrinolytic parameters.

Authors:  Koichi Saotome; Yasumori Koguchi; Kazuya Tamai; Hiroya Sakai; Wataru Ohno; Minoru Yamato
Journal:  J Orthop Sci       Date:  2003       Impact factor: 1.601

Review 8.  Rheumatological management of patients with hemophilia. Part II: Muscle hematomas and pseudotumors.

Authors:  Michel Alcalay; Adeline Deplas
Journal:  Joint Bone Spine       Date:  2002-12       Impact factor: 4.929

9.  Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII.

Authors:  G R Milner; P J Holt; J Bottomley; J E Maciver
Journal:  J Clin Pathol       Date:  1977-08       Impact factor: 3.411

Review 10.  Acquired factor XIII deficiency: a therapeutic challenge.

Authors:  Françoise Boehlen; Alessandro Casini; Carlo Chizzolini; Behrouz Mansouri; Hans Peter Kohler; Verena Schroeder; Guido Reber; Philippe de Moerloose
Journal:  Thromb Haemost       Date:  2013-01-10       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.